[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"axial-spondylarthritis-axspa\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:axial-spondylarthritis-axspa":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,72,94,127],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100634120","phase-2-the-investigators-will-evaluate-the-diagnostic-performance-of-18f-alf-fapi-74-petct-in-inflammatory-disorders-and-compare-it-with-the-current-gold-standard-for-inflammation-fdg-petct-in-three-patient-cohort-patients-presenting-with-fever-of-unknown-origin-igg4-rd-and-axspa-100634120",false,"NCT07535554","The Investigators Will Evaluate the Diagnostic Performance of [18F]-AlF-FAPI-74 PET\u002FCT in Inflammatory Disorders and Compare it With the Current Gold Standard for Inflammation, FDG PET\u002FCT, in Three Patient Cohort: Patients Presenting With Fever of Unknown Origin, IgG4-RD and AxSpA.","Prospective Diagnostic Performance of PET\u002FCT Using the Novel Fibroblast Imaging Tracer [18F]-AlF-FAPI-74 Versus Standard of Care [18F]-FDG in Inflammatory Disorders","Inclusion Criteria FUO:\n\n* An illness of more than 3 weeks' duration,\n* Temperature exceeding 38.3°C on \\> 3 occasions, or elevated inflammatory markers on \\> 3 occasions\n* Diagnosis uncertain despite appropriate first-line investigations.\n\nInclusion criteria IgG4-RD:\n\n* High clinical suspicion of IgG4-RD by an experienced clinician of Internal Medicine, based on anamnesis, physical examination, first-line investigations and blood tests.\n* Patients with a new diagnosis of IgG4-RD on histopathology and need for further assessment of disease extent with PET\u002FCT,\n* Relapse of diagnosed IgG4-RD on histopathology according to an experienced clinician of Internal Medicine\n\nInclusion criteria AxSpA:\n\n* High clinical suspicion of axial spondyloarthropahy according to an experienced rheumatology (based on inflammary back pain \\> 3 months, insidious onset, morning stifness, improvement with exercise and worsening in rest, pain worse at night, age at onset \\\u003C45 years of age, imaging findings).\n* Patient has persisting inflammatory back pain after 2 different types of NSAID's (tried for over 2-4 weeks), and is therefore eligible for biological DMARDS therapy.\n\nExclusion Criteria:\n\n* Participant is mentally or legally incapacitated, doesn't understand the study design or is not willing or capable to undergo all study-specific procedures.\n* Any disorder or condition, which in the Investigator's opinion might jeopardise the participant's safety or compliance with the protocol.\n* Any prior or concomitant treatment(s) that might jeopardise the participant's safety or that would compromise the integrity of the Trial.\n* Female who is pregnant (urinary hCG test will be performed in every WOCBP), breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate, highly effective contraceptive (with a relatively high Pearl Index: natural methods, minipill outside postpartum period, spermicides or condoms in monotherapy or no usage of contraception when sexually active are not accepted).\n* Participation in an interventional Trial with an investigational medicinal product (IMP) or device when the trial designs are not considered compatible by the study team.\n* Participation in a clinical scientific study in the last 12 months with a radiation exposure caused by the experimental procedures greater than 1 mSv.\n* Participant has a known hypersensitivity to \\[18F\\]AlF-FAPI-74 or the used excipients.\n* Active treatment has already commenced","ALL","18 Years",{"count":19,"type":20},140,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE2","PHASE3","The aim of the study to evaluate the performance of new \\[18F\\]-AlF-FAPI-74 PET\u002FCT in three inflammatory disorders (fever of unknown origin, IgG4-related disease and axial spondyloarthritis) and compare with the current stand-of-care \\[18F\\]-FDG PET\u002FCT",[27,28,29,30],"Fever of Unknown Origin","IgG4 Related Disease","Axial Spondylarthritis (axSpA)","Inflammation of Unknown Origin","RECRUITING","2026-04-14",{"date":34,"type":35},"2026-04-17","ACTUAL",{"date":37,"type":35},"2025-09-17",{"date":39,"type":20},"2030-03-31",{"name":41,"class":42},"Universitaire Ziekenhuizen KU Leuven","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":43},"100594343","phase-4-impact-of-upadacitinib-on-the-frequency-of-acute-recurrent-anterior-uveitis-in-patients-with-axial-spondyloarthritis-100594343","NCT07018206","Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis","Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis (UP-FOR-U)","UP-FOR-U","Inclusion Criteria:\n\n1. Subject ≥18 of age at the screening visit.\n2. Subject must be able to understand and willing to adhere to all protocol requirements and voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)\u002Finstitutional review board (IRB), prior to the initiation of any screening or study-specific procedures.\n3. Diagnosis of axSpA by their treating rheumatologist.\n4. Classification of axSpA according to ASAS Classification Criteria\n5. History of at least one acute anterior uveitis event in the 52 week period prior to baseline, diagnosed by an ophthalmologist.\n6. Active disease as defined by a BASDAI value of ≥4 and TBP score of ≥4 (on a 0-10 NRS scale) at screening and baseline.\n7. History of an inadequate response to at least two different NSAIDs over a period of 4 weeks in total at the maximum recommended or tolerated doses, or intolerance\u002Fcontraindication (e.g., allergic reaction, gastrointestinal symptoms or signs, severe arterial hypertension, etc.) for NSAIDs.\n8. Subjects must have been treated for ≥3 consecutive months prior to the study entry with bDMARD therapy and\u002For for ≥4 weeks of NSAID therapy, in accordance with local product label for AS or nr-axSpA, but continue to exhibit active SpA, or had to discontinue previous bDMARD and\u002For NSAID treatment due to intolerability or toxicity, irrespective of treatment duration. A total of 50 subjects who are bDMARD-naïve and 150 subjects who are b-DMARD-IR will be included in the study.\n9. For all females of child-bearing potential: must not have a positive serum pregnancy test at the Screening Visit and must have a negative urine pregnancy test at Baseline prior to the first dose of study drug (local practices may require serum pregnancy testing at Baseline). Subjects with a borderline serum pregnancy test at Screening must have absence of clinical suspicion of pregnancy or other pathological causes of borderline results and a serum pregnancy test ≥3 days later to document continued lack of a positive result (unless prohibited by local requirements).\n10. Subjects who are regularly taking NSAIDs or analgesics (including low potency opioids) as part of their axSpA therapy are required to be on a stable dose\u002Fdose regimen for at least 7 days prior to the baseline visit. If entering the study on concomitant tramadol, combination of acetaminophen\u002Fparacetamol and codeine or combination of acetaminophen\u002Fparacetamol and hydrocodone, and\u002For non-opioid analgesics, subject must be on stable dose(s) for at least 7 days prior to the baseline Visit. However, subject must not have used opioid analgesics (except for combination of acetaminophen\u002Fparacetamol and codeine or combination of acetaminophen\u002Fparacetamol and hydrocodone which are allowed) within 7 days prior to the BL Visit.\n11. Subjects taking oral corticosteroids must be on an average daily and stable dose of ≤10mg\u002Fday prednisone or equivalent for at least 14 days prior to the baseline visit.\n12. Subjects entering the study on the following concomitant csDMARDs must be on a stable dose as indicated below for at least 28 days prior to the baseline Visit (in case of Leflunomide washout must be either 11 days with colestyramine or 30 days with activated charcoal or as per local label). A combination of up to 2 background csDMARDs is allowed EXCEPT the combination of methotrexate (MTX) and leflunomide. • MTX (≤ 25 mg\u002Fweek); or • Sulfasalazine (SSZ) (≤ 3 g\u002Fday); or • Hydroxychloroquine (≤ 400 mg\u002Fday); or • Chloroquine (≤ 250 mg\u002Fday); or • Leflunomide (≤ 20 mg\u002Fday)\n13. If subjects are currently taking bDMARD therapy, they may be recruited after an appropriate wash-out period of bDMARD prior to the Baseline Visit. Washout periods are as follows: 4 weeks for Etanercept, 8 weeks for Infliximab, Golimumab, and Certolizumab, 10 weeks for Adalimumab, and Ixekizumab, 12 weeks for Secukinumab. However, subjects should not stop their previous successful biological therapy only to be included in this study. For subjects intolerant to bDMARD and not on such treatment a washout period may not be necessary.\n\nExclusion Criteria:\n\n1. Active infection(s) requiring treatment with parenteral anti-infectives within 30 days, or oral antiinfectives within 14 days prior to the baseline Visit; Chronic recurring infection and\u002For active viral infection that based on the investigator's clinical assessment makes the subject an unsuitable candidate for the study.\n2. COVID-19: In subjects who tested positive for COVID-19, at least 5 days must have passed between a COVID-19 positive test result and the Baseline visit of asymptomatic subjects. Subjects with mild\u002Fmoderate COVID-19 infection can be enrolled if fever is resolved without use of antipyretics for 24 hours and other symptoms improved, or if 5 days have passed since the COVID-19 positive test result (whichever comes last). Subjects may be rescreened if deemed appropriate by the investigator based upon the subject's health status\n3. Suspected COVID-19: subjects with signs\u002Fsymptoms suggestive of COVID-19, known exposure, or high-risk behavior should undergo molecular (e.g., PCR) testing to rule out SARS-CoV-2 infection or must be asymptomatic for 5 days from a potential exposure;\n4. History of recurrent (more than one episode) herpes zoster or disseminated\u002Fmulti-dermatomal (a single episode) herpes zoster or disseminated (a single episode) herpes simplex.\n5. Primary or secondary immunodeficiency.\n6. Subjects with active TB or who meet TB exclusionary parameters (specific requirements for TB testing are provided in Section 7.0: TB Testing\u002FTB Prophylaxis)\n7. Chronic infection with hepatitis B virus. At screening HBsAg and anti-HBc will be tested. Subjects who are HBsAg positive will be excluded. In case of HBsAg negativity, but anti-HBc positivity, participation in the study is possible if HBV-DNA testing is negative and no exclusionary liver function tests.\n8. Chronic infection with hepatitis C (HCV) (HCV ribonucleic acid (RNA) detectable in any subject with anti-HCV antibody (HCV Ab), or Human Immunodeficiency Virus (HIV) infection confirmed by positive HIV-antibody and antigen test.\n9. Female subjects who are breastfeeding, pregnant, or plan to become pregnant during the study or within 4 weeks following the last dose of study drug.\n10. Subjects with chronic inflammatory articular disease (other than axSpA or systemic autoimmune diseases, e.g., systemic lupus erythematosus, Sjögren´s syndrome, RA, unequivocal chronic fatigue syndrome, or unequivocal fibromyalgia. Subjects with a diagnosis of Crohn's disease or ulcerative colitis are allowed as long as they have no active symptomatic disease within 4 weeks prior to BL.\n11. Concomitant treatment with strong inductors or inhibitors of cytochrome P450 3A (e.g., Ketoconazole, Fluconazole, Rifampicin, Clarithromycin, St-John´s-wort).\n12. Prior treatment with upadacitinib or another JAK-inhibitor or TYK2-inhibitor for axSpA.\n13. History of hypersensitivity to any component of upadacitinib tablets.\n14. Treatment with intravenous, intramuscular or intraarticular\u002Fperiarticular, or intrarectal steroids within 4 weeks prior to baseline Visit; treatment with oral steroids in a dose of \\>10 mg prednisolone equivalent per day within 4 weeks prior to baseline visit.\n15. Subject must not have been treated with any investigational drug of chemical or biologic nature within a minimum of 30 days or five half-lives (whichever is longer) prior to the first dose of study drug or is currently enrolled in another interventional clinical study.\n16. History of an infected joint prosthesis at any time, with the prosthesis still in situ.\n17. Actual malignancies or history of malignancies with curative treatment within 5 years prior to screening, except successfully treated non-metastatic squamous cell or basal cell carcinoma of the cutis or carcinoma in situ of the cervix.\n18. A subject with any condition possibly affecting oral drug absorption, e.g., gastrectomy, clinically significant diabetic gastroenteropathy, or certain types of bariatric surgery such as gastric bypass. Procedures such as gastric banding, that simply divides the stomach into separate chambers, are NOT exclusionary.\n19. Significant trauma or surgery procedure within 4 weeks prior to baseline.\n20. Evidence of other severe uncontrolled gastrointestinal, hepatic (serum albumin \\\u003C25 mg\u002Fl or ChildPugh-Score \\>10), renal, pulmonary, cardiovascular, nervous or endocrine disorders.\n21. Any history of prior cardiovascular event, including but not limited to cerebrovascular accident, myocardial infarction, coronary stenting, and aorto-coronary bypass surgery.\n22. History of thrombosis and\u002For hematological disorder increasing the propensity to thrombosis.\n23. Any subject who has been vaccinated with live or attenuated vaccines within the 4 weeks prior to the first dose of study medication or is to be vaccinated with these vaccines at any time during treatment or within 4 weeks after the last dose of study drug.\n24. Any of the following lab abnormalities detected at screening: a) Hemoglobin \\\u003C9 g\u002Fdl; b) Absolute neutrophil count (ANC) \\\u003C1.2 x 109\u002FL (\\\u003C1020\u002Fmm3) c) Absolute lymphocyte count (ALC) \\\u003C0.750 x 109\u002FL (\\\u003C750\u002Fmm3) d) Platelet count \\\u003C9 g\u002FdL e) Liver function tests (LFT) \\>2 x ULN f) Serum apartate transaminase (AST) \\>2 x ULN g) Serum alanine transaminase (ALT) \\>2 x ULN; h) Estimated glomerular filtration rate (GFR) by simplified 4-variable MDRD formula \\\u003C 30 mL\u002Fmin\u002F1.73 m2; i) Total white blood cell (WBC) count \\\u003C 2,500\u002FμL",{"count":53,"type":20},200,[55],"PHASE4","This is a Phase IV, open-label, multicenter study evaluating the impact of upadacitinib on the frequency of acute anterior uveitis (AAU) in adults with axial spondyloarthritis (axSpA) and a documented history of AAU in the prior 52 weeks. Approximately 200 participants will be enrolled across North America and Europe, including both biologic DMARD-inadequate responders (bDMARD-IR) and bDMARD-naïve patients. The primary objective is to assess the change in exposure-adjusted AAU event rate during 52 weeks of treatment with upadacitinib 15 mg once daily. Secondary objectives include evaluating the effect of upadacitinib on disease activity, pain, physical function, quality of life, and sleep. Safety and tolerability will also be assessed throughout the study.",[29],[59,60],"Axial Spondyloarthritis","Acute Anterior Uveitis","NOT_YET_RECRUITING","2026-02-04",{"date":64,"type":35},"2026-02-06",{"date":66,"type":20},"2026-05",{"date":68,"type":20},"2027-05",{"name":70,"class":71},"CARE ARTHRITIS LTD.","INDUSTRY",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":43},"100605730","treatment-effectiveness-in-people-with-axspa-or-psa-starting-treatment-with-bimekizumab-risankizumab-guselkumab-upadacitinib-or-a-tnf-inhibitor-100605730","NCT07166315","Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor","Clinical Characteristics, Treatment Patterns and Outcomes in Patients With axSpA and PsA Following Initiation of Bimekizumab, Risankizumab, Guselkumab, Upadacitinib or a TNF Inhibitor","Inclusion Criteria:\n\n* Participant has a clinical diagnosis of axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA).\n* Participant has been prescribed advanced therapy within one month prior to enrolment in the study, to treat their axSpA or PsA.\n* Participant is aged 18 years or older at enrolment.\n\nExclusion Criteria:\n\n-Participation in a clinical trial at enrolment.",{"count":80,"type":20},700,"OBSERVATIONAL","This observational study will target patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who have started treatment with bimekizumab, upadacitinib, risankizumab, guselkumab, or a tumour necrosis factor-alpha inhibitor (e.g., adalimumab or etanercept) at NHS hospitals in the United Kingdom. Information from patients' medical records will be collected, and patients will complete surveys about their experiences with their treatment. The study will look at treatment effectiveness from both healthcare professionals' and patients' points of view.",[29,84],"Psoriatic Arthritis (PsA)","2025-09-09",{"date":87,"type":35},"2025-09-10",{"date":89,"type":35},"2025-07-07",{"date":91,"type":20},"2027-03",{"name":93,"class":71},"Adelphi Real World",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":102,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":43},"100604475","clinical-assessment-for-rheumatologic-disease---research-and-advancement-in-safety-and-efficacy-100604475","NCT07150000","Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy","CARe RAiSE Study - Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy","CARe RAiSE","Inclusion Criteria:\n\n* Participants aged ≥ 18 years\n* Signed written informed consent to participate voluntarily in the study.\n* Confirmed diagnosis (by the treating physician) of one of the following autoimmune or autoinflammatory rheumatic diseases:\n* Rheumatoid arthritis (RA)\n* Psoriatic arthritis (PsA)\n* Axial spondyloarthritis (axSpA)\n* Giant cell arteritis (GCA)\n* Connective tissue diseases, including:\n\n  1. Systemic lupus erythematosus (SLE)\n  2. Systemic sclerosis (SSc)\n  3. Mixed connective tissue disease (MCTD)\n  4. Idiopathic inflammatory myopathies (IIM)\n* ANCA-associated vasculitides (AAV), including:\n\n  1. Microscopic polyangiitis (MPA)\n  2. Granulomatosis with polyangiitis (GPA)\n  3. Eosinophilic granulomatosis with polyangiitis (EGPA)\n* Autoinflammatory diseases, including\n\n  1. Familial Mediterranean fever (FMF)\n  2. Cryopyrin-associated periodic syndromes (CAPS)\n  3. TNF receptor-associated periodic syndrome (TRAPS)\n  4. Adult-onset Still's disease (AOSD)\n\n     Exclusion Criteria:\n* Refusal to participate in the study or inability to provide informed consent.\n\nInclusion Criteria - Healthy Control Group:\n\n* Participants aged ≥ 18 years (capable of providing informed consent).\n* Signed written informed consent to participate voluntarily in the study.\n\nExclusion Criteria - Healthy Control Group:\n\n\\- Presence of a known or active rheumatologic disease.",true,{"count":104,"type":20},120,"The CARe RAiSE project represents a pioneering translational initiative aimed at advancing precision medicine in the treatment of autoimmune rheumatic diseases. The primary objective is the development and implementation of an innovative cell-based ex vivo assay that enables individualized prediction of therapeutic response to disease-modifying antirheumatic drugs (DMARDs). By identifying the most effective treatment option for each patient, this approach seeks to enhance therapeutic efficacy, reduce time to clinical response, and minimize healthcare costs.\n\nDespite the availability of numerous DMARDs, clinical decision-making remains largely empirical due to considerable interindividual variability in treatment response. This frequently results in a prolonged trial-and-error process, placing a significant burden on patients and the healthcare system. CARe RAiSE aims to overcome this limitation by providing a functional diagnostic tool that can predict a patient's immunological response to specific DMARDs prior to treatment initiation.\n\nThe assay is based on peripheral blood mononuclear cells (PBMCs) obtained from individual patients, enabling a physiologically relevant assessment of immune responsiveness to targeted therapies. Combining high-content imaging with homogeneous well-based cytokine and inflammasome activity assays, the platform allows for a detailed single-cell analysis of inflammatory pathways. These data are used to generate predictive signatures of treatment response, thereby facilitating a mechanistically informed and personalized therapeutic strategy.\n\nThrough this approach, CARe RAiSE introduces a scientifically grounded, efficient, and patient-specific method for DMARD selection, with the potential to substantially improve patient outcomes and reduce the socioeconomic impact of autoimmune rheumatic diseases.",[107,108,109,84,29,110,111,112,113,114,115,116,117],"Rheumatic Diseases","Rheumatoid Arthritis (RA)","Giant Cell Arteritis (GCA)","Polymyalgia Rheumatica (PMR)","ANCA Associated Vasculitis (AAV)","Connective Tissue Disease (CTD)","Systemic Sclerosis (SSc)","Systemic Lupus Erthematosus (SLE)","Idiopathic Inflammatory Myopathy (IIM)","Autoinflammatory Disease","Gout Arthritis","2025-08-24",{"date":120,"type":35},"2025-09-02",{"date":122,"type":35},"2025-04-01",{"date":124,"type":20},"2028-12",{"name":126,"class":42},"University of Bonn",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":21,"phases":138,"briefSummary":140,"conditions":141,"keywords":142,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":151,"locationsCount":153},"100603784","initial-standardized-global-review-in-axial-spondyloarthritis-100603784","NCT07141017","Initial Standardized Global Review in Axial Spondyloarthritis","Evaluating the Impact of an Initial Standardized Global Review in Patients With Early Axial Spondyloarthritis: a Multicenter Randomized Cluster-controlled Study","REVINSPA","Inclusion Criteria:\n\n* Adults (but age \\\u003C80years) with a diagnosis of axial spondyloarthritis determined by the treating rheumatologist within the 12 months preceding the baseline visit, who have completed the informed consent and have the ability to complete all study activities.\n\nExclusion Criteria:\n\n* Patients who have already received a specific (or plan to receive in the coming 12 months) and dedicated program\u002Fglobal evaluation including education on the disease or treatments.\n* Patients with any physical or mental condition that may affect understanding of the intervention or adherence to treatment (e.g. major depression or substance\u002Falcohol use - might have impact on the outcomes of interest in the study).","80 Years",{"count":137,"type":20},154,[139],"NA","This study will be a pragmatic, cluster-randomized, controlled study with two parallel arms ( 'intervention' and 'usual care' (UC) arms) of one year duration.\n\nThe study will be open-label, but centers randomized in the UC arm will not be aware of the intervention performed in the 'intervention' centers.\n\nThe primary objective of this study will be to determine whether participation in a standardized global review (that includes assessment of disease domains and education ) as soon as possible after diagnosis of axial spondyloarthritis has a beneficial impact on patient knowledge of the disease at 12 months. The primary endpoint will be the change in the SPAKE (SPondyloArthritis Knowledge Questionnaire) questionnaire between M0 and M12.",[29],[143,144],"Rheumatology","Initial standardized global review","2025-08-18",{"date":147,"type":35},"2025-08-26",{"date":149,"type":35},"2025-05-12",{"date":68,"type":20},{"name":152,"class":42},"Association de Recherche Clinique en Rhumatologie",21]